ERBB2 and breast cancer: Ongoing studies, such as the DESTINY-Breast06 trial, are currently evaluating ADCs in patients with HER2-ultra-low BC, who could benefit from new conjugated HER2-targeted therapies in the cohort previously scored as 0 HER2 [61].